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Abstract
Background: Patients with lymphoma are at risk of experiencing adverse physical and psychosocial problems from
their cancer and its treatment. Regular screening of these symptoms by the use of patient-reported outcomes (PROs)
could increase timely recognition and adequate symptom management. Moreover, self-management interventions
intend to enhance knowledge and skills and empower patients to better manage their disease and related problems.
The objective of the Lymphoma InterVEntion (LIVE) trial is to examine whether feedback to patients on their PROs and
access to a web-based, self-management intervention named Living with lymphoma will increase self-management
skills and satisfaction with information, and reduce psychological distress.
Methods/design: The LIVE randomised controlled trial consists of three arms: (1) standard care, (2) PRO feedback, and
(3) PRO feedback and the Living with lymphoma intervention. Patients who have been diagnosed with
Hodgkin lymphoma, non-Hodgkin lymphoma, including chronic lymphocytic leukaemia, as registered in the
Netherlands Cancer Registry in various hospitals will be selected for participation. Patients are invited via their
haemato-oncologist 6 to 15 months after diagnosis. The PRO feedback includes a graphical overview of patients’ own
symptom and functioning scores and an option to compare their scores with those of other patients with lymphoma
and a normative population of the same age and sex. The Living with lymphoma intervention is based on cognitive
behavioural therapy components and includes information, assignments, assessments, and videos. Changes in
outcomes from baseline to 16 weeks, 12, and 24 months post intervention will be measured. Primary outcomes
are self-management skills, satisfaction with information, and psychological distress. Secondary outcomes are
health-related quality of life, illness perceptions, fatigue, and health care use.
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Discussion/design: The results of the LIVE trial will provide novel insights into whether access to PRO feedback
and the Living with lymphoma intervention will be effective in increasing self-management skills and satisfaction
with information, and reducing distress. The LIVE trial is embedded in a population-based registry, which provides
a unique setting to ascertain information on response, uptake, and characteristics of patients with lymphoma in
web-based intervention(s). When effective, PRO feedback and Living with lymphoma could serve as easily and
widely accessible interventions for coping with lymphoma.
Trial registration: Netherlands Trial Register, identifier NTR5953. Registered on 14 July 2016.
Keywords: Lymphoma, Intervention, Self-management, Psychological distress, Information provision, Patient-
reported outcomes, PRO feedback, Population-based, Randomised controlled trial
Background
Due to advances in treatment, the 20-year prevalence of
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma
(NHL) in the Netherlands is expected to increase by 5% to
6300 and 32,000 patients in 2020, respectively [1, 2]. As a
result of their cancer and its treatment, patients with
lymphoma are at risk of experiencing adverse physical and
psychosocial problems, such as fatigue, neuropathy, and
cognitive and emotional problems [3–6]. Patients who re-
port adverse problems have a lower health-related quality
of life (HRQoL) and visit their physician more often [7–9].
In addition, up to a quarter of patients with lymphoma ex-
perience persistent levels of anxiety, depressive feelings,
and fears, also called psychological distress [7, 10].
Patient-reported outcomes (PROs) intend to evaluate
the impact of a disease and its treatment from the per-
spective of the patient [11]. PROs are being increasingly
recognised to be important in daily practice [12, 13].
Regular screening of physical and psychosocial symp-
toms by the use of PROs could increase awareness and
recognition of symptoms and can contribute to adequate
symptom management [11, 14–17]. Moreover, the
greater the resources available for coping with symptoms
and stress, the lower the risk for psychological distress
[18]. Interventions using cognitive behavioural therapy
(CBT) components, such as psychoeducation and coping
skills, can reduce persistent psychological distress and
physical problems and improve HRQoL [8].
As the number of patients surviving lymphoma con-
tinues to grow, interventions need to be easily accessible
without increasing the burden on health services. Self-
management interventions can be effective in strengthen-
ing the role of patients, by increasing patient engagement
in care, and limiting the burden on health services
[19, 20]. Self-management interventions aim to em-
power patients to have an active role in the manage-
ment of their disease and its symptoms and
consequences including treatment, physical, and psycho-
social and lifestyle changes [21, 22]. Web-based technolo-
gies are particularly suitable for self-management
interventions since they are easily accessible, can reach a
large number of patients [19, 23], and provide more
anonymity compared to face-to-face interventions [24].
Therefore, web-based interventions have the potential to
eliminate barriers to psychosocial care for patients with
cancer. However, it is important that such interventions
should be evidence-based and empirically tested [25].
The Lymphoma InterVEntion (LIVE) trial consists of
two interventions: (1) feedback to patients on their
PROs, and (2) a web-based, self-management interven-
tion named Living with lymphoma. Patients will be
randomised to: (1) standard care, (2) standard care plus
access to PRO feedback or (3) standard care plus access
to PRO feedback and the Living with lymphoma inter-
vention. PRO feedback enables patients to monitor their
symptoms and compare them with outcomes among
other patients. This may help to either reassure that
what they experience is ‘normal’ or may empower them
to take action. The Living with lymphoma intervention
is based on CBT components and is an adaptation from
the evidence-based BREAst cancer e-healTH (BREATH)
intervention [26]. By using the Living with lymphoma
intervention, patients will receive psychoeducation and
learn coping skills which they can apply as self-
management skills in daily life.
Methods/design
Objectives and hypotheses
The objective of the LIVE trial is to examine whether
PRO feedback and the Living with lymphoma inter-
vention will increase self-management skills and satis-
faction with information and reduce psychological
distress. In concordance with the stress-coping model
of Lazarus and Folkman (1984), psychological adjust-
ment after cancer is determined by the balance be-
tween stress and resources [18]. Therefore, it is
hypothesised that patients with access to PRO feed-
back and/or the Living with lymphoma intervention
will report increased self-management skills and satis-
faction with information (greater resources available
for coping), and lower levels of psychological distress
compared to patients receiving standard care.
Arts et al. Trials  (2017) 18:199 Page 2 of 11
Moreover, it is expected that patients with access to
both PRO feedback and the Living with lymphoma
intervention will benefit most.
Study design
The LIVE trial is designed as a nonblinded randomised
controlled trial with three arms. For an overview of the
design of the trial, see Fig. 1. Standard care plus the
access to PRO feedback and the Living with lymphoma
intervention (arm 3) will be compared to standard care
plus access to PRO feedback (arm 2) and standard care
(arm 1). Patients with lymphoma from various hospitals
in the Netherlands will be included and asked to
complete questionnaires at four points in time: baseline
(T0; 6 to 15 months after diagnosis), after 16 weeks (T1;
post intervention), after 12 months (T2), and after
24 months (T3).
Study population
All patients who have been diagnosed with HL or NHL,
including chronic lymphocytic leukaemia (CLL), as de-
fined by the International Classification of Diseases for
Oncology-3 codes (ICD-O-3) [27], in the participating
hospitals will be selected for participation via the
Netherlands Cancer Registry (NCR). Patients must be
aged 18 years or older at the time of diagnosis. Patients
who have problems with the Dutch language, patients with
severe psychopathology or dementia, and patients in tran-
sition to terminal care will be excluded from the study.
Setting
The LIVE trial will be conducted within the Patient
Reported Outcomes Following Initial treatment and
Long-term Evaluation of Survivorship (PROFILES) regis-
try [28]. PROFILES is a tool that enables data collection
management; from inviting patients to participation in
studies, to collecting PRO data via web-based or mailed
questionnaires and linking these data with clinical data.
Since this trial is embedded in the population-based
PROFILES lymphoma registry, we have access to infor-
mation on response, uptake, and user characteristics of
patients with lymphoma in a web-based intervention.
Recruitment
The population-based NCR of the Netherlands Compre-
hensive Cancer Organisation (IKNL) will be used to
Recruitment
Baseline completion of questionnaires
(T1)
Online (T0)
Randomization
Yes 
T1
T2
T3
ARM 1:
Standard care
T1
T2
T3
ARM 2:
Access to PRO 
feedback
T1
T2
T3
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Access to
PRO feedback
+
Living with lymphoma 
intervention
Paper-and-pencil 
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Fig. 1 Overall study design of the Lymphoma InterVEntion (LIVE) trial
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select all patients in the participating hospitals who meet
the inclusion criteria. The NCR registers all newly diag-
nosed cancer patients within 6 months after diagnosis.
After excluding deceased patients, the treating haemato-
oncologists are asked to verify the patients’ study eligibil-
ity. All eligible patients will be invited for participation by
their own haemato-oncologist. The haemato-oncologists
will provide the eligible patients with an invitation pack-
age, including an invitation letter and leaflet to inform
them about the study, a postcard, and two Informed
Consent Forms (i.e. one for the researchers and one for
the patient). The letter explains the study objectives and
includes a link and password to a secure website so that
patients can complete questionnaires online. If patients
prefer paper-and-pencil participation, they can complete
the postcard and return it by mail to the study manager.
Patients will then receive paper-and-pencil questionnaires
and a pre-stamped envelope within 1 week of receipt of
the postcard. Patients are informed that paper-and-pencil
participation automatically means that they will not be
able to participate in the LIVE trial and only participate in
the observational PROFILES lymphoma registry, as both
PRO feedback and the Living with lymphoma intervention
are web-based.
If the questionnaire is not completed within 3 weeks, a
reminder will be sent by the treating haemato-
oncologists. After obtaining informed consent, the sub-
sequent communication to the patients will be addressed
via PROFILES. To guarantee anonymity, questionnaires
only contain a study number.
Randomisation
Patients who complete the baseline questionnaire online
and consent to participate in the LIVE trial will be auto-
matically randomised in an equal ratio (1:1:1) to one of
the three study arms: (1) standard care, (2) standard care
plus access to PRO feedback or (3) standard care plus
access to PRO feedback and the Living with lymphoma
intervention. This randomisation will be performed
using block randomisation. The randomisation will be
performed by a computer randomisation program which
will ensure a balance in sample size across groups over
time [29].
Interventions versus standard care
Arm 1: Standard care
For patients randomised to arm 1, the haemato-
oncologist provides standard care. Most haemato-
oncologists give their patients leaflets regarding the
diagnosis and treatment they receive. Most informa-
tion is given during the initial treatment phase, and
some of the haemato-oncologists give additional infor-
mation during follow-up for ad hoc referrals if needed
by the patient. Patients who receive standard care can
use information about lymphoma on the Internet, but
do not have access to PRO feedback or the Living
with lymphoma intervention.
Arm 2: PRO feedback
Patients randomised to arms 2 and 3 have access to
PRO feedback, including general HRQoL, physical, emo-
tional, cognitive and social functioning, fatigue, neur-
opathy (only for patients with high-grade NHL), and
anxiety and depressive symptoms.
Patients can compare their scores to mean scores of
other patients with lymphoma (same sex and age group)
and/or a normative population (same sex and age group)
to find out whether their scores are average or not
(using a traffic light model). A detailed description of
how to interpret the scores is added to assist patients in
understanding the graphs. Mean scores of the lymphoma
sample are extracted from data of our previous research
on HRQoL among 856 patients with lymphoma [30].
The normative population was selected from a reference
cohort of 1859 individuals from the general Dutch popu-
lation (CentERpanel). This cohort is representative for
the Dutch-speaking population in the Netherlands [31].
Individual scores will be integrated into graphical dis-
plays with coloured bar-charts [32, 33]. The colours of
the bar-charts are related to clinically relevant mean dif-
ferences of the evidence-based guidelines of the EORTC
QLQ-C30 [34]. A score that differs less than the min-
imal medium clinically relevant difference from the
mean score is considered ‘average’ (amber). A score that
differs as much as or more than the minimal medium
clinically relevant difference from the mean score is con-
sidered ‘above average’ (green) or ‘below average’ (red).
The interpretation of anxiety and depressive symptoms
is according to the published scoring algorithm: 0–7 in-
dicating no or mild symptoms (green), 8–10 indicating
moderate symptoms (amber), and ≥11 indicating severe
symptoms (red) [35]. Patients with a score in the red
part of the chart are advised to contact their general
practitioner. For an example of PRO feedback, see Fig. 2.
To review the PRO feedback, patients have to click on
the ‘feedback’ tab after completing the questionnaire. Pa-
tients can decide not to review their PRO feedback as
they prefer not to.
Arm 3: PRO feedback plus Living with lymphoma
intervention
In addition to PRO feedback, patients randomised to
arm 3 get access to the Living with lymphoma inter-
vention. This web-based self-management intervention
is an adaptation of the evidence-based BREATH inter-
vention for breast cancer survivors [26, 36]. The con-
tent of the intervention is adapted to warrant its
relevance for patients with lymphoma. Symptoms that
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are typically common in patients with lymphoma,
such as neuropathy, infections, and infertility, have
been added.
One key feature of the intervention is the ‘work space’
that includes four phases: (1) ‘looking back’, (2) ‘emo-
tional processing’, (3) ‘strengthening’, and (4) ‘looking
ahead’. For a screenshot of the ‘work space’, see Fig. 3.
The intervention is based on CBT techniques, such as
psychoeducation, to enhance patients’ knowledge and
skills, for instance by providing tailored advices based on
patients’ input. Working ingredients of the four phases
include information, assignments, assessments, and vid-
eos. The information part provides patients with know-
ledge on various subjects such as adverse physical and
psychological problems, work, sexuality, and lifestyle.
Assignments are, for example, writing tasks, social en-
gagement or conversation tasks and aim to increase
skill-building [26]. Assessments include tests that could
be used by patients as a screening instrument of poten-
tial problems and are followed by automated feedback.
Videos are clips extracted from recorded interviews with
patients with lymphoma.
Another feature of the intervention is the library with
background and additional information on subjects from
the four phases (e.g. work, sexuality, lifestyle). For a
screenshot of the library, see Fig. 4. The library also con-
tains links to additional health care services (e.g. psy-
chologists, physiotherapists, dieticians).
The advised intervention usage is one part per week,
with a duration of approximately 1 h. However, it is up
to the patients how, and to what extent, they use the
intervention. From the BREATH intervention it is
known that patients use the website quite diversely [37].
The intervention is fully automated and nonguided and
is delivered without the professional support of a therap-
ist. Support for content or technical assistance is avail-
able by the study manager.
Study outcome measures
Patient demographics and clinical information will be
available from the NCR that routinely collects data on,
among other things, patients’ age and sex, date of cancer
diagnosis, histological classification, stage, treatment, and
comorbidity. Information on marital status, educational
Fig. 2 An example of patient-reported outcome feedback
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level, and employment status are gathered by self-report
using questionnaires.
Primary outcomes
Self-management skills are measured by the Health
Education Impact Questionnaire (heiQTM) [38]. The
heiQTM contains 40 items across eight scales: positive
and active engagement in life, health-directed activities,
skill and technique acquisition, constructive attitudes
and approaches, self-monitoring and insight, health ser-
vice navigation, social integration and support, and emo-
tional distress. Each item will be scored on a four-point
Likert scale. The scale scores are obtained by computing
the mean of respective items. Higher scores indicate bet-
ter status or self-management, except for emotional dis-
tress, in which higher scores indicate higher distress
[38]. The heiQTM has high construct validity [38]. Five
scales of the heiQTM are validated among patients with
cancer [39].
Psychological distress will be assessed by the 14-item
Hospital Anxiety and Depression Scale (HADS) [35]. A
sum score is obtained by adding the items. Its rating
system is based on a four-point format and asks how
the patient has felt in the past week. Higher scores indi-
cate higher levels of psychological distress. The HADS
has shown good reliability and validity in oncology set-
tings [40, 41].
Satisfaction with information will be measured by an
adapted version of the 9-item Information Satisfaction
Questionnaire (ISQ) [42]. The ISQ has been widely
used to assess overall information satisfaction and the
need for involvement in decision-making. The original
measure requires patients to categorise themselves into
one of three groups: those who would like (1) all avail-
able information and to be involved in decisions about
their illness, (2) only positive information about the
illness, and (3) only limited information and would pre-
fer the doctor to make the decisions. However, Fallow-
field suggests that there is a distinction between the
desire for information and involvement in decision-
making [43]. Therefore, we divided that question into
two items, one assessing the desire for information and
one assessing the desire for involvement in decision-
making. Patients are, furthermore, asked to rate their
level of satisfaction with the information that they have
received about their illness, treatment, and lifestyle.
Each of these questions will be scored on a five-point
Likert scale. The English version of the ISQ was trans-
lated into Dutch by forward-backward translation pro-
cedures. Questions about desire for more or less
Fig. 3 Screenshot from the ‘work space’ of the Living with lymphoma intervention with phase structure (in Dutch)
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information, helpfulness of information, and the use of
the Internet (to search for information) were added to
the questionnaire.
Secondary outcomes
Health-related quality of life―general will be assessed
using the Dutch validated European Organisation for
Research and Treatment of Cancer (EORTC) Quality of
Life Questionnaire (QLQ-C30) [44]. This 30-item ques-
tionnaire includes five functional scales, three symptom
scales, a global health and quality of life scale, and
several single-item symptom measures. All items will be
scored on a four-point Likert scale, except for the global
health and quality of life scale that is scored on a seven-
point linear analogue scale. After linear transformation,
all scales and single-item measures range in score from
0 to 100. Higher scores on functional and health and
quality of life scales indicate better functioning or
HRQoL, whereas higher scores on symptom scales indi-
cate more symptoms.
Health-related quality of life―lymphoma-specific will be
assessed with the EORTC disease-specific modules, i.e.
QLQ-HL27 for HL, QLQ-NHL-HG29 for high-grade
NHL and QLQ-NHL-LG20 for low-grade NHL, and
QLQ-CLL17 for CLL [45]. The modules are divided into
multi-item subscales including symptom burden, physical
condition/fatigue, worries/fears, health and functioning,
emotional impact, and neuropathy (only in the NHL-
HG29 module). Items are scored on a four-point Likert
scale. After linear transformation, all scales range in score
from 0 to 100, whereby a higher score reflects more
problems [45].
Self-efficacy with regard to symptoms (in this study as
a result of lymphoma) will be measured with the Self-
efficacy Scale (SE28) [46–48]. This scale consists of
seven items, which will be scored on a four-point Likert
scale. A higher score reflects a greater sense of control.
This scale had previously been used to assess self-
efficacy concerning post-cancer fatigue [49].
Adjustment to cancer will be assessed using the 40-item
Mental Adjustment to Cancer Scale (MAC) [50]. Items
are rated on a four-point Likert scale. The summary scales
(i.e. summary positive adjustment scale, summary negative
adjustment scale) can be used to identify general adjust-
ment styles for cancer. The summary positive adjustment
scale includes 17 items and scores range from 17 to 68
Fig. 4 Screenshot from the library of the Living with lymphoma intervention (in Dutch)
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(cut-off ≥47), whereas the summary negative adjustment
scale includes 16 items with scores ranging from 16 to 64
(cut-off ≥36) [51]. Summary scales are scored through
addition of the items.
Illness perceptions will be assessed using the validated
Brief Illness Perception Questionnaire (B-IPQ) [52]. This
scale has nine items, measuring cognitive representations,
emotional representations, and illness comprehensibility.
Items are scored on a continuous linear 0–10-point scale.
A higher score reflects a more threatening view of the ill-
ness. The B-IPQ has been previously cross-culturally
adapted into the Dutch Language Version (Brief IPQ-
DLV), with acceptable face and content validity [53].
Fatigue will be assessed with the 20-item validated
Multidimensional Fatigue Inventory (MFI) [54]. The
MFI covers five scales: general fatigue, physical fa-
tigue, reduced activity, reduced motivation, and men-
tal fatigue. Each scale contains four items, with two
items formulated in a positive (e.g. ‘I feel fit’) and
two formulated in a negative direction (e.g. ‘I feel fa-
tigued’). All items are scored on a five-point Likert
scale. The negatively formulated items must be
recoded before adding up scores. Higher sum scores
correspond to more acute levels of fatigue. The MFI
is reliable and valid to assess fatigue in patients with
cancer [54].
Health care use will be assessed by single items: ‘How
often did you contact a general practitioner in the past
12 months?’, ‘How many of these visits were related to
cancer of the consequences of your cancer?’, ‘How often
did you visit a medical specialist in the past 12 months?’,
‘How many of these visits were related to cancer or to
the consequences of your cancer?’ These questions were
asked in a similar way as by Statistics Netherlands [55]
(http://statline.cbs.nl/). Three questions are asked about
follow-up appointments (whether or not receiving
follow-up appointment, the frequency of follow-up ap-
pointments, and satisfaction with this frequency). Fur-
thermore, patients are asked whether they visited a
psychologist, psychiatrist or social worker and the last
question was ‘Did you receive care after the treatment of
your cancer?’ To answer this question, patients could
either choose ‘No’ or ‘Yes’ and then choose multiple
additional care services from a list: sexologist, pastoral
care, dietician, physical therapist, oncological rehabilita-
tion, creative therapy, oncology nurse, or contact with
other cancer survivors.
Covariates
Comorbidity at the time of survey will be assessed with
the adapted Self-administered Comorbidity Question-
naire (SCQ) [56]. Patients will be asked to identify co-
morbid conditions that have developed since diagnosis.
Personality will be assessed using the Big Five Inven-
tory (BFI) [57]. The BFI is a 44-item inventory designed
to measure the Big Five dimensions: extraversion, agree-
ableness, conscientiousness, neuroticism, and openness
to experience. Items are scored on a five-point Likert
scale. Scale scores will be created by averaging the items
for each domain. The Dutch BFI has good psychometric
quality [58].
Usage statistics
In addition to the standardised questionnaires, technical
data on the use of the intervention, such as frequency,
duration, and activity, will be evaluated.
Sample size calculation
Sample size calculation was performed using G*Power
version 3.1.9.2 for Windows. Based on the three primary
outcomes of this trial, effect on patient level is defined
as increased self-management skills or satisfaction with
information (as measured by the heiQTM and the ISQ,
respectively) or reduced psychological distress (as mea-
sured with the HADS). Therefore, effectiveness of LIVE
is demonstrated when one of the three effects is statisti-
cally significant. Significance level of the sample size
calculation was adjusted to p ≤ 0.167 to keep the overall
chance for type-I errors at 5%.
Clinically important differences will be determined with
Norman’s ‘rule of thumb’, whereby a difference of approxi-
mately 0.5 SD indicates a threshold of discriminant
change in quality of life scores of a chronic illness [59]. To
detect a clinically important difference with 90% power, a
sample size of 222 patients with lymphoma (74 in each
group) is needed. This sample size calculation is based on
a medium effect size of 0.25 for repeated measures ana-
lysis of variance (ANOVA) with two measurements, since
at least two measurements are necessary to compare pre-
intervention and postintervention outcomes. We take into
account a response rate of 70% as observed in earlier stud-
ies (of them 60% are expected to complete the question-
naires online) and a study dropout rate of 25%, based on a
systematic review on adherence to Internet interventions
for anxiety and depression [60]. This results in 663
patients with lymphoma who need to be invited for
participation.
Statistical analyses
All statistical analyses will be performed using Statistical
Analyses Software (SAS; version 9.4 for Windows, SAS
Institute Inc., Cary NC, USA). Analyses on effectiveness
of the intervention will be primarily done according to
intention-to-treat methodology. Second, per-protocol
analysis will be performed to analyze the efficacy of the
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intervention. All statistical tests will be two-sided and
considered significant if p < 0.05.
Missing outcome data will be assumed to be ‘missing
at random’ (MAR), conditional on key predictors of
‘missingness’ (in particular, baseline values of the out-
come variables of interest, and study arm).
Patients’ sociodemographic and clinical variables will be
compared at baseline between the three study arms using
chi-square analyses for categorical variables and ANOVA
for continuous variables and will be analysed as covariates.
Repeated measures analysis using generalised estimat-
ing equations, which account for the intra-patient de-
pendency of the repeated measures, will be used to
analyse the effect of the intervention on the outcome
variables. We will investigate differences in effect of the
two intervention arms and the arm receiving standard
care at the different time points. Differential effects of
the intervention arms by age, cancer subtype, and base-
line levels of the outcomes of interest will be assessed
for the outcome measures by adding terms for the inter-
action between age, cancer subtype, baseline levels, and
care arm to the regression models.
Routinely collected data from the population-based
NCR on patient and tumour characteristics will enable
us to compare paper-and-pencil respondents with online
respondents, as well as respondents with nonrespon-
dents and patients with unverifiable addresses in order
to determine the external validity of the results and an-
swer our second study objective.
Discussion
Regular screening of symptoms by the use of PROs and
access to resources for coping skills could help to detect
and/or manage symptoms that up to a quarter of pa-
tients with lymphoma are experiencing.
The results of the LIVE trial will provide novel insights
into whether access to PRO feedback and the Living with
lymphoma intervention will be effective in increasing
self-management skills and satisfaction with information,
and reducing psychological distress. Since one third of
patients will be randomised to solely access to PRO
feedback and not to the Living with lymphoma interven-
tion, it will be possible to investigate the superiority of
access to PRO feedback as well as the superiority of ac-
cess to PRO feedback and the Living with lymphoma
intervention compared to standard care.
The LIVE trial is embedded in the population-based
PROFILES lymphoma registry, which provides a unique
setting to ascertain information on response, uptake,
and characteristics of patients with lymphoma in web-
based intervention(s). This information is important
with respect to the generalisability of results and, more-
over, it demonstrates which patient subgroups will bene-
fit most from PRO feedback and the Living with
lymphoma intervention. Patients will not be selected
based on their symptoms or distress level prior to study
entry and it is up to patients themselves how, and to
what extent, they use the intervention(s). When effect-
ive, access to PRO feedback and the Living with lymph-
oma intervention could serve as easily and widely
accessible interventions for coping with lymphoma in
the Netherlands.
Trial status
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